Research paper

Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women

Gabriela Baldeon-Vaca, Jai G. Marathe, Joseph A. Politch, Emilie Mausser, Jeffrey Pudney, James Doud, Ellena Nadora, Larry Zeitlin, Michael Paulyc, Thomas R. Moench, Miles Brennan, Kevin J. Whaley, Deborah J. Anderson

Division of Medical Sciences, Boston University School of Medicine, Boston, MA 02118, United States
Mapp Biopharmaceutical, Inc., 6160 Lusk Blvd., San Diego, CA 92121, United States
Department of Medicine, Boston University School of Medicine, 670 Albany St. Rm 516, Boston, MA 02118, United States

Keywords:
Contraception, Non-hormonal, Monoclonal antibody, Antisperm antibody, Nicotiana, Sperm

1. Introduction

Over the past 200 years the human population has grown from under 1 billion to over 7.7 billion individuals, and is on track to exceed 10 billion by the end of this century [1, 2]. Many population experts have voiced concern that this rapid rate of population growth exerts dangerous pressure on planetary resources and is unsustainable. Despite the availability of numerous effective birth control methods, over 40% of pregnancies worldwide are unintended. These pregnancies are significantly contributing to population growth, and unintended pregnancies can have pronounced adverse effects on maternal physical, mental, and economic wellbeing [1]. There is an urgent need for new contraception methods to address the problem of unintended pregnancies. The majority of effective female contraceptive methods require medical visits and/or procedures which can introduce economic and accessibility barriers. Among the most widely used reversible contraceptives, hormonal methods are frequently discontinued due to side effects, and barrier methods often fail due to inconsistent or improper use [3–6]. New non-hormonal, woman-controlled methods that are safe, accessible, inexpensive, and discrete could provide an important contribution to the contraception field. Recent surveys indicate that women find two approaches highly desirable: on-demand contraception, and multi-purpose prevention technology (MPT) products that provide dual protection against unintended pregnancy and sexually transmitted infections. "Antisperm antibody against CD52g for topical contraception in women."

EBioMedicine 69 (2021) 103478

ARTICLE INFO

Article History:
Received 1 April 2021
Revised 18 June 2021
Accepted 21 June 2021
Available online 10 July 2021

Keywords:
Contraception, Non-hormonal, Monoclonal antibody, Antisperm antibody, Nicotiana, Sperm

ABSTRACT

Background: Approximately 40% of human pregnancies are unintended, indicating a need for more acceptable contraceptive methods. New antibody production systems make it possible to manufacture reagent-grade human monoclonal antibodies (mAbs) for clinical use. We used the Nicotiana platform to produce a human antisperm mAb and tested its efficacy for on-demand topical contraception.

Methods: Heavy and light chain variable region DNA sequences of a human IgM antisperm antibody derived from an infertile woman were inserted with human IgG1 constant region sequences into an agrobacterium vector and transfected into Nicotiana benthamiana. The product, an IgG1 mAb (“Human Contraception Antibody” (HCA)), was purified on Protein A columns, and QC was performed using the LabChip GXII Touch Protein characterization system and SEC-HPLC. HCA was tested for antigen specificity by immunofluorescence and western blot assays, antisperm activity by sperm agglutination and complement dependent sperm immobilization assays, and safety in a human vaginal tissue (EpiVaginal™) model.

Findings: HCA was obtained at concentrations ranging from 0.4 to 4 mg/ml and consisted of > 90% IgG monomers. The mAb specifically reacted with a glycan epitope on CD52g, a glycoprotein produced in the male reproductive tract and found in abundance on sperm. HCA potently agglutinated sperm under a variety of relevant physiological conditions at concentrations ≥ 6.25 μg/ml, and mediated complement-dependent sperm immobilization at concentrations ≥ 1 μg/ml. HCA and its immune complexes did not induce inflammation in EpiVaginal™ tissue.

Interpretation: HCA, an IgG1 mAb with potent sperm agglutination and immobilization activity and a good safety profile, is a promising candidate for female contraception.

Funding: This research was supported by grants R01 HD095630 and P50HD096957 from the National Institutes of Health.

© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Research in context

Evidence before this study

We chose to pursue an antisperm monoclonal antibody for contraception because there is an extensive literature about antisperm antibodies and infertility. A substantial percentage of infertile men and women have antisperm antibodies in genital secretions that affect sperm function, and for many years infertile patients were screened for these antibodies. The World Health Organization convened a Contraceptive Vaccine Task Force in 1985, and in conjunction with this program a number of scientists developed antisperm monoclonal antibodies (mAbs) to characterize sperm antigens with potential for use in contraceptive vaccines. A leading antisperm mAb, H6-3C4, was made by a Japanese group by hybridizing lymphocytes from an infertile woman with mouse hybridoma cells. The WHO’s contraceptive vaccine project was discontinued following criticism that the efficacy of an antisperm vaccine might vary depending on the strength of the immune response in vaccinated women, and that it could be difficult to reverse a strong infertility effect.

Added value of this study

Passive immunization with preformed antisperm antibodies would circumvent the concerns raised over active immunization with sperm for contraception. Over the past 10 years, the field of passive immunization has gained traction due to improved cloning techniques for human mAbs, and new production platforms. In this translational research project we transfected the variable region gene sequence from the H6-3C4 mAb into a modern platform, Nicotiana benthamiana, used to make clinical grade mAbs, to produce a human antisperm mAb suitable for contraception. We demonstrate that the IgG1 mAb is specific, agglutinates sperm within 15 seconds, does not cause irritation, and remains active in vaginal conditions (low pH, diverse microflora) for up to 24 hours.

Implications of all the available evidence

This antibody appears to be suitable for contraceptive use. It could be administered vaginally in a film for a woman-controlled on-demand method, and could be combined with other antibodies such as anti-HIV and anti-HSV antibodies for a multipurpose prevention technology. Such products may be acceptable to women who do not use currently available contraception methods, and could have a significant impact on global health as unintended pregnancies constitute 40% of all pregnancies and often adversely affect maternal health and economic well-being.
than the length of time it takes sperm to reach the endocervical canal (estimated to occur 3–5 min post-insemination [24–26]). Two blinded, trained laboratory personnel independently observed agglutination to avoid bias. Safety assessments included mAb specificity testing by immunofluorescence and western blot assays, and evaluation of vaginal tissue for proinflammatory cytokines following treatment with HCA and HCA immuno-complexes. These assays were repeated at least twice to confirm the results. S19, a commercially available mouse anti-CD52 mAb, was used as a positive control, and CAMPATH, a commercially available rat anti-human CD52 mAb, and Anti-CD52g mAbs were tested for specificity on washed human spermatozoa and human peripheral blood mononuclear cells (PBMCs, negative control). Cells were smeared on glass slides, air dried and fixed in acetone, and incubated with 25, 50 or 100 μg/mL of HCA, S19 or CAMPATH mAbs. VRC01-N, a human IgG1 mAb produced in Nicotiana and directed against the HIV-1 envelope glycoprotein gp120, was used as an isotype-matched negative control antibody for HCA. A mouse mAb directed against CD3, a prominent T lymphocyte surface protein (Santa Cruz Biotechnology Cat# sc-20047, Santa Cruz, CA, USA), RRID: AB_627014) was used as an isotype-matched control antibody for S19. Primary antibodies were detected with a 1:200 dilution of fluorophore-conjugated secondary antibodies against mouse (Jackson ImmunoResearch Cat# 715-165-149, RRID: AB_2340538), human (Jackson ImmunoResearch Cat# 709-166-149, RRID: AB_2340813), or rat Igs (Jackson ImmunoResearch Cat# 712-165-153, RRID: AB_2340687) (All from Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).

### 2.2. Antibodies

#### 2.2.1. Human contraception antibody (HCA)

The human anti-CD52g mAb, HCA, was produced in Nicotiana benthamiana by Mapp Biopharmaceutical Inc. (San Diego, CA, USA). Genes containing the variable region sequences of H-6-3C4 [16, 19] were synthesized by Life Technologies (San Diego, CA, USA) and cloned into TMV and PVX plant expression vectors [27] containing codon-optimized human lambda and human IgG1 constant regions. The vectors were then transformed into Agrobacterium tumefaciens strain ICF320 (Icon Genetics; Halle/Saale, Germany) which was used to transfect 4-week old Nicotiana plants by vacuum infiltration as previously described [22]. Seven days post-infiltration, antibody was extracted from the leaf tissue and purified by Protein A chromatography as previously described [22, 28]. The Nicotiana plants used for this study were a transgenic strain in which fucosyl- and xylosyl- transferases were knocked down with RNAi so that the antibodies they produced had a humanized glycosylation pattern [21, 29]. HCA QC was performed using multiple instruments/assays including the LabChip GXII Touch protein characterization system (quantification, purity, molecular weight sizing), SEC-HPLC, BioRad CFX real time PCR detection (thermal melt), and a Wyatt DynaPro Plate Reader II (DLS).

#### 2.2.2. S19

Mouse anti-CD52g mAbs were obtained from the supernatant of S19 hybridoma cells originally established by John Herr (ATCC Cat# HB-12144, Manassas, VA, USA) [30–32]. S19 hybridoma cells were grown in complete Iscove’s Modified Dulbecco’s Medium (IMDM, ATCC Manassas, VA, USA) with 10% fetal bovine serum (FBS), 1% Penicillin Streptomycin, and 1% L-Glutamine 200mM (Gibco, ThermoFisher Scientific, Waltham, MA, USA). For antibody harvesting, hybridomas were seeded at confluence in IMDM without FBS and cultured until most cells died [33]. The supernatant was collected and mAbs were concentrated with a 15mL, 50-kDa centrifuge filter (UFC905096, Millipore Sigma, Burlington, MA, USA) at 3,000 x g for 40 min. S19 antibody was resuspended in PBS and quantified by nanodrop. Antibody was stored in Multipurpose Handling Media (MMH; FUJIFILM Irvine Scientific; Santa Ana, CA, USA) at 4°C.

#### 2.2.3. CAMPATH-1

CAMPATH-1 is a commercially available rat mAb, clone YTH34.5, directed against a peptide epitope on CD52 (ThermoFisher Scientific Cat# MA5-16999, Waltham, MA, USA, RRID: AB_2538471).

### 2.3. Tests of antibody specificity

#### 2.3.1. Immunofluorescence assay

Anti-CD52g mAbs were tested for specificity on washed human spermatozoa and human peripheral blood mononuclear cells (PBMCs, negative control). Cells were smeared on glass slides, air dried and fixed in acetone, and incubated with 25, 50 or 100 μg/mL of HCA, S19 or CAMPATH mAbs. VRC01-N, a human IgG1 mAb produced in Nicotiana and directed against the HIV-1 envelope glycoprotein gp120, was used as an isotype-matched negative control antibody for HCA. A mouse mAb directed against CD3, a prominent T lymphocyte surface protein (Santa Cruz Biotechnology Cat# sc-20047, Santa Cruz, CA, USA, RRID: AB_627014) was used as an isotype-matched control antibody for S19. Primary antibodies were detected with a 1:200 dilution of fluorophore-conjugated secondary antibodies against mouse (Jackson ImmunoResearch Cat# 715-165-150, RRID: AB_2340813), human (Jackson ImmunoResearch Cat# 709-166-149, RRID: AB_2340538) or rat Igs (Jackson ImmunoResearch Cat# 712-165-153, RRID: AB_2340687) (All from Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).

#### 2.3.2. Immunohistology

Antibodies were tested for reactivity on a variety of human reproductive tract tissues (cauda epididymis, vas deferens, vagina) and tonsil. Paraffin-embedded tissues were sectioned at 5 μm, de-waxed, hydrated, and subjected to antigen retrieval which was carried out by immersing the sections in a citrate buffer, pH 6, and then placing the tissues in a pressure cooker that was heated to 125°C for 30 seconds (Biocare Medical, Concord, CA). The sections were incubated with Cy3-labeled HCA or VRC01 (conjugation kit: Abcam, Cambridge, MA, USA) at a 1:20 dilution overnight at 4°C. Finally, the sections were mounted in AntiFade Mounting Medium with DAPI. All sections were examined under an Olympus microscope (Olympus America Inc. Melville, NY) fitted with epifluorescence imaging and images were captured with a digital camera.

#### 2.3.3. Scanning electron microscopy

Sperm that had been treated with HCA or PBS (control) were air dried on coverslips and fixed in 0.5 strength Karnovsky’s fixative for 48 h. Coverslips were then rinsed in PBS and dehydrated in a series of ethanol concentrations– 35, 50, 70, 95% (1x for 10 min) and 100% (3x for 10 min) before critical point drying in a Tousimis semi-automatic Critical Point Dryer. Coverslips were mounted on aluminum stubs and coated with chromium in a GATAN Ion Beam Coater. Images were taken with a JEOL 7401F Field Emission Scanning Electron Microscope.

#### 2.3.4. Western blot

Human sperm, seminal plasma, and VK2/E6E7 cells (vaginal epithelial cell line used as a negative control [34]) (VK2/E6E7, ATCC Cat# CRL-2616, RRID: CVCL-6471) were lysed by radioimmunoprecipitation...
2.4. Tests of antibody function

2.4.1. Semen analysis and sperm preparation

Healthy men between the ages of 18–45, with semen samples meeting the WHO criteria for fertility [23], provided fresh semen samples for this study. The samples were processed within one hour of collection, after liquefaction. Live sperm were obtained by passage of semen through 90% Isolate density gradient medium (FUJIFILM Irvine Scientific; Santa Ana, CA, USA). Briefly, whole semen was layered over an equivalent volume of Isolate. The sample was centrifuged at 300xg for 20 min, and the pellet containing live, motile sperm was resuspended in MHM. Sperm count and motility were assessed by Computer-Assisted Sperm Analysis (CASA; Human Motility II software, CEROS II, Hamilton Thorne, Beverly, MA, USA) utilizing the recommended settings by the manufacturer. Both whole semen and washed motile sperm were used for the functional assays described below.

2.4.2. Agglutination kinetics assay

Two microliters of sperm suspension were pipetted onto a 9mm well microscope slide (ThermoScientific, Waltham, MA, USA), and an equivalent amount of antibody in MHM was added. Antibody and sperm were mixed by quickly pipetting the mixture up and down three times, and sperm agglutination was observed in real-time on an Olympus inverted microscope at 10X. The time it took for sperm to become completely (100%) agglutinated was recorded by two trained independent readers blinded to experimental variables. For the recommendation of the manufacturer. Both whole semen and washed motile sperm were used for the functional assays described below.

2.4.3. Modified sperm swim-up ("sperm escape") assay

The "Sperm Escape Assay" was developed by us to assess the percentage of progressively motile free-swimming sperm that remained in the supernatant following treatment with HCA. MAbs were diluted in MHM, and 30 μL were added to upright 0.2mL PCR tubes. Thirty μL of motile sperm suspension or whole semen were then added to the antibody and the contents were mixed three times by pipetting. Tubes were placed at a 45° angle and the mixture was incubated for 5 min at room temperature to allow agglutinated and immotile sperm to settle to the bottom of the tube. A 2.5 μL sample was taken from the top millimeter of the mixture and placed in a 4-chambered slide (Microcell 15424, Vitrolife, San Diego, CA, USA). The sample was analyzed by CASA to determine the total sperm concentration and the number of progressively motile sperm that had escaped agglutination.

2.4.5. Complement-dependent sperm immobilization assay

Washed sperm with an initial motility > 90% were adjusted to a concentration of 25–40 × 10^6/mL in MHM. Human serum, separated from fresh whole blood by centrifugation, was used as the complement source. Heat-inactivated (HI) complement (heated to 56 °C for 30 min) was used as the control. Five μL of complement or HI-complement were incubated with 2.5 μL of sperm suspension for 5 min at room temperature. Next, 25 μL of HCA were added in a series of two-fold dilutions (3.125–0.20 μg/mL) and mixed; 3 μL of the suspension were transferred to 4-chambered slides in duplicate and the slides were incubated in a humidified chamber at 32 °C for 1 h. Sperm motility was assessed using the CERSO II CASA. A minimum of three trials was performed using different semen donors.

2.5. Testing HCA activity under various physiological conditions

2.5.1. Whole semen vs. washed sperm

To compare the ability of HCA to agglutinate sperm in whole semen and in washed sperm suspensions, the semen samples were divided into two fractions: (1) whole unprocessed semen, and (2) Isolate- prepared washed motile sperm resuspended in MHM to the same concentration as that of the original semen sample. Sperm from two to three donors were pooled for these experiments. Agglutination Kinetics and Sperm Escape Assays were performed as described above.

2.5.2. Effect of sperm concentration

Motile sperm were isolated from semen using Isolate, and resuspended in MHM at concentrations ranging from 2 to 100 × 10^6/mL.

2.5.3. Effect of low pH

The pH of MHM was lowered to 3.5 using D/L-lactic acid (Sigma Aldrich, MA, USA). HCA was incubated in acidic (pH 3.5) or neutral (pH 7.0) MHM for 0, 2, 4, and 24 h at 37 °C. Following incubation, the low pH MHM was neutralized by addition of HEPES Buffer (Invitrogen) and neat seminal plasma. The antibody was then used in the Agglutination Kinetics Assays.

2.5.4. Effects of female genital secretions

HCA was incubated in cervicovaginal lavage (CVL) supernatant (1:1 vol) for up to 24 h at 37 °C. CVLs from healthy women without bacterial vaginosis (BV) were added to MHM at concentrations ranging from 2 to 100 × 10^6/mL.

2.6. Preclinical safety assessment

2.6.1. Vaginal tissue cytokine response assay

The EpiVaginal™ tissue model (MatTek Cat# VEC-100FT, MatTek Corporation, Ashland, MA, USA) was used to study potential proinflammatory effects of HCA and HCA immune complexes. This tissue model has been validated for vaginal irritation studies [35]. A total of 100 μL of different combinations of HCA (100 μg/mL), semen and complement (C) were added to the upper chamber (apical side) of the EpiVaginal™ tissue. Tissues were incubated at 37 °C for 6 h after which the antibody/sperm/complement suspensions were washed off, and 80 μL of MatTek EpiVaginal Tissue Media was added to the upper chamber. After 24 h, apical and basal supernatants were collected and cytokines were measured using a custom 6-plex ProcartaPlex Luminex kit (Invitrogen, ThermoFisher Cat# PPX-06, ThermoFisher Scientific, Waltham, MA, USA).
HCA antigen specificity was confirmed by immunohistology and western blot. HCA and control antibodies were tested by indirect immunofluorescence assay on acetone-fixed washed human sperm and peripheral blood mononuclear cells (PBMCs, negative control). HCA, S19, and CAMPATH reacted with the entire sperm surface, whereas VRC01 showed no reactivity (Fig. 2A–D, respectively). HCA, S19, and VRC01 did not react with PBMCs, whereas CAMPATH did as expected [32] (Fig. 2E–G). Tissue immunohistochemistry was also used to demonstrate HCA specificity. Cy3-conjugated HCA reacted with epithelial cells in the human cauda epididymis and its luminal contents containing sperm (Fig. 2I), but did not react with human vaginal or tonsil tissue (Fig. 2J,K). Cy3-conjugated VRC01 (isotype control) did not react with any of the tissues (Fig. 2L–N). In the western blot assay, HCA detected a ~15–25 kDa band in seminal plasma and sperm lysates, the expected size of heavily glycosylated CD52g. The band was undetectable following treatment of sperm lysates with PNGase F, an enzyme that cleaves N-linked glycans (Fig. 2O, left panel). CAMPATH, which targets the peptide backbone on CD52g, also reacted with the ~15–25 kDa band in sperm lysates; after PNGase F treatment of sperm, CAMPATH detected a lower MW band representing CD52g without N-glycans (Fig. 2O, right panel). None of the antibodies reacted with lysates of VK2 cells, an immortalized human vaginal epithelial cell line [34] used for negative control.

3.2. Functional assays

3.2.1. Sperm agglutination kinetics assay

At a concentration of 100 μg/mL, HCA agglutinated 100% of sperm in under 15 s (Figs. 3A and 2C). Scanning electron microscopy of HCA-treated sperm revealed a mixed agglutination pattern: head-to-head, head-to-tail, tail-to-tail (Fig. 3B). Effective agglutination time varied with HCA concentration; at HCA concentrations ≥ 12.5 μg/mL, complete sperm agglutination occurred within 20 s, whereas at an HCA concentration of 6.25 μg/mL complete agglutination occurred in 50 s (Fig. 3C). At a concentration of 1.5 μg/mL, complete agglutination had not occurred by 120 s. CAMPATH and VRC01 did not agglutinate sperm at any concentration (Fig. 3A).

3.2.2. Sperm escape assay

A modified sperm swim-up assay was used to evaluate the number of progressively motile sperm that escape from sperm agglutinates following exposure to HCA; agglutinated and immotile sperm sink to the bottom of the tube, whereas sperm with progressive motility can be recovered from the upper fraction of the sperm suspension (Fig. 3D). These progressively motile sperm are the antibody “escapees” that could potentially fertilize an ovum. At HCA concentrations ranging from 100 to 12.5 μg/mL, the number of motile sperm in the swim-up fraction was < 2% of the media control; at the lowest HCA concentration tested (6.25 μg/mL), the number of progressively motile sperm in the swim-up fraction was 5% of media control (Fig. 3E).

3.2.3. Complement-dependent sperm immobilization

A modified sperm immobilization test was used to determine whether HCA induces complement (C)-dependent sperm immobilization, another mechanism that may mediate antibody-mediated infertility [36, 37]. Since HCA potently agglutinates sperm at concentrations ≥ 6.25 μg/mL, HCA concentrations < 6.25 μg/mL were used to visualize and quantify individual sperm. With the addition of active human complement, there was a significant decrease in the number of motile sperm (p < 0.0001); significant sperm immobilization was observed at HCA concentrations as low as 0.78 μg/mL (Fig. 3F). HCA did not immobilize sperm in the presence of heat-inactivated complement (negative control).

3.3. HCA activity under physiologically relevant conditions

3.3.1. Washed sperm vs. whole semen

We tested the ability of HCA to agglutinate sperm in the presence and absence of seminal fluid because sperm are delivered to the

Table 1

| Test Parameter                 | Test Method         | Specification                      |
|-------------------------------|---------------------|------------------------------------|
| General Characteristics       |                     |                                    |
| pH                            | Visible Appearance  | Clear liquid, no visible particulates |
| Osmolality                    |                     | 6.5 ± 0.5 10–100 mOsm/kg           |
| Protein Concentration         | UV Absorbance (A280)| 15–25 mg/mL                        |
| Identity                      | IEX-HPLC            | Chromatogram Forms to Standard     |
| Purity                        | Size Exclusion HPLC | > 90% Monomer < 5% HMW Species     |
|                               | SDS-PAGE Reduced, Coomassie Stained | > 95% (Sum of Heavy and Light Chains) |
|                               | SDS-PAGE Non-Reduced, Coomassie Stained | > 90% Main Band                       |
| Safety                        | Endotoxin           | < 5 EU/mg                           |
|                               | Bioburden           | ≤ 1 CFU/mL                          |
| Impurities                    | Residual Host Cell DNA | < 50 pg/mg                           |
|                               | Residual Protein A ELISA | < 100 ng/mg                          |
|                               | Residual Host Cell Protein A ELISA | < 100 ng/mg                          |

HMW = High Molecular Weight
vagina in seminal fluid, but rapidly swim away from the insemination site. We hypothesized that the kinetics could be different since seminal plasma contains high concentrations of soluble CD52g which could compete with CD52g on sperm for HCA binding. At HCA concentrations ≥ 25 μg/ml, the difference between sperm agglutination times in whole semen compared to washed sperm was not significant. At 6.25 and 12.5 μg/ml, the time to agglutination was significantly greater in whole semen compared to washed sperm (p < 0.05, Fig. 4A), but even at these low antibody concentrations, sperm in whole semen were agglutinated in less than 60 s. We also compared the ability of HCA to agglutinate sperm in whole semen versus washed sperm preparations using the sperm escape assay. At HCA concentrations ≥ 12.5 μg/ml, the number of progressively motile sperm in the swim-up fraction was < 5% of media-treated sperm for both whole semen and washed sperm preparations (p > 0.05, NS). At 6.25 μg/ml, the fraction of progressive sperm remained < 5% for washed sperm samples but increased to 15% for whole semen samples (p < 0.01, Fig. 4B).

3.3.2. Effect of sperm concentration

We tested the effect of sperm concentration on antibody-induced sperm agglutination since agglutination is dependent on sperm

Fig. 2. Specificity testing of HCA. Indirect immunofluorescence of sperm with (A) HCA, (B) S19, (C) CAMPATH, and (D) VRC01 [isotype control for HCA]. Indirect immunofluorescence of PBMCs with (E) HCA, (F) S19, (G) CAMPATH, and (H) VRC01. Reactivity of Cy3-labeled HCA in (I) human cauda epididymis, (J) vaginal, and (K) tonsil tissue. (L-N) Lack of reactivity of Cy3-labeled VRC01 (isotype control) with the same tissues. L = Lumen. All images 20x magnification. (O) Western blots of HCA, S19 and CAMPATH antibodies tested on electrophoresed lysates of human seminal plasma (SP), sperm, PNGaseF-treated sperm (Sperm –), and VK2 cells (negative control).
collisions and antibody bridging. Agglutination could be less efficient at low sperm concentrations where antibody-antigen interactions occur at a lower frequency; at higher sperm concentrations effective agglutination could require higher antibody concentrations due to larger amounts of available antigen. Sperm concentrations in human ejaculates can vary from 0 sperm/mL (azoospermia) to greater than 200 × 10^6/mL [23]. Men with sperm concentrations ≤ 15 × 10^6/mL are oligozoospermic, a condition associated with reduced fertility [23, 38, 39], and men with ≤ 1 × 10^6 sperm/mL have severe oligospermia and a very low fertility rate. Male contraception studies aim to reduce sperm concentrations to ≤ 1 × 10^6/mL [40]. We tested the ability of HCA to agglutinate sperm over a wide range of physiological

---

**Fig. 3.** HCA effectively agglutinates human sperm (A) Time-elapse photography of 1:1 mixtures of washed sperm (100 × 10^6/mL) and 100 μg/mL of mAbs (HCA, CAMPATH, VRC01). Sperm agglutination was monitored using an inverted microscope (10x). (B) SEM images of HCA-agglutinated sperm and PBS control. All images at 1500x. (C) Agglutination kinetics assay using ~30 × 10^6/mL washed sperm and various concentrations of HCA. “Seconds to agglutination” is the time taken for sperm in a 10x field of view to fully agglutinate. Each data point is the average of triplicate reads (Two-way ANOVA with multiple comparisons). (D) Schematic of the sperm escape assay, a modified swim-up assay that measures progressive sperm that escape HCA-induced agglutination. (E) Sperm escape assay using ~30 × 10^6/mL washed sperm. Y-axis depicts the percentage of progressive sperm present in the supernatant of HCA-treated samples compared to media control. Each bar indicates results with washed sperm and red bars indicated results with whole semen. Each bar indicates the average of triplicate reads (Two-way ANOVA with multiple comparisons). (F) Complement-dependent sperm immobilization test. HI = heat inactivated complement (****p-value < 0.0001). Error bars represent ± SD values.
sperm concentrations by adjusting the concentration of sperm in ejaculates from normal sperm donors. As shown in Fig. 4C, HCA concentrations ≥ 6.25 µg/mL effectively agglutinated sperm within one minute at sperm concentrations ranging from 12.5 × 10⁶ to 100 × 10⁶/mL, indicating that sperm within the fertile concentration range agglutinated effectively. At the lowest sperm concentration tested, 2 × 10⁶/mL, agglutination occurred within 70 s at HCA concentrations ranging from 25 to 100 µg/mL; at the lowest HCA concentration (6.25 µg/mL), the sperm did not agglutinate within 2 min. Overall, sperm concentrations in the fertile range agglutinated within an acceptable length of time at HCA concentrations ≥ 6.25 µg/mL.

3.3.3. Effect of low pH and female genital secretions

We performed most of the functional assays for this study at neutral pH because the vaginal pH is neutral after intercourse due to the addition of alkaline semen [41]. However, for HCA to successfully be used as a topical product in the vaginal tract, it must withstand physiological conditions in the vagina before intercourse. Vaginal secretions from reproductive-aged women generally have an acidic pH [42, 43]. We tested the effects of HCA and HCA immune complexes in an in vitro model of vaginal integrity and inflammation. Combinations of antibody, semen, and human complement were added to the apical side of MatTek EpiVaginal™ tissues [35] and incubated for 6 h. After washing the apical side of the tissues and allowing cytokines to be secreted into fresh media for 24 h, the apical and basal supernatants were collected and cytokine concentrations were measured by Luminex (Fig. 5A). Semen treatment increased levels of IL-1β and IL-6 in the apical supernatants irrespective of the presence of HCA and/or complement [46, 47] (Fig. 5B). Notably, cultures treated with HCA alone, HCA + C, and HCA + C + semen did not exhibit additional upregulated expression of proinflammatory cytokines by the vaginal epithelial cultures. Histology of the treated tissues showed that tissues were morphologically intact after treatment with HCA immune complexes (Fig. 5C).

4. Discussion

In this study we engineered an antisperm mAb associated with human infertility [18] for use as a topical contraceptive agent. We demonstrated that it is possible to produce a high-quality antisperm human IgG1 mAb (HCA) using the cost-effective Nicotiana production
platform. We next confirmed antibody activity and specificity. HCA was specific for MRT-CD52g; the antibody reacted with sperm but did not bind to peripheral blood mononuclear cells, or tonsil or vaginal tissue. We then assessed antibody antisperm function in two classical assays: the sperm agglutination and complement dependent sperm immobilization assays. HCA was highly effective at agglutinating and immobilizing sperm over a wide concentration range. Studies are currently underway to determine whether HCA prevents sperm penetration through cervical mucus, which could be another protective mechanism [48].

To determine whether the HCA mAb retains antisperm function in the vaginal environment, activity was tested under a variety of physiologically relevant conditions. HCA effectively agglutinated sperm after prolonged exposure to low pH or to cervicovaginal secretions from women with normal and abnormal vaginal microflora, and retained activity in the presence of seminal plasma which contains soluble CD52g. The mAb was also effective over a wide range of sperm concentrations. Pre-clinical safety assessment using the EpiVaginal™ tissue model indicated that the mAb and its immune complexes did not affect vaginal tissue integrity or induce proinflammatory cytokine release; this was an expected outcome since IgG along with IgA isotype antibodies are naturally found in vaginal secretions [49–53].

Human mAbs are attractive candidates for vaginal contraception and MPT because they are natural mediators of protection at mucosal sites and would enhance existing antibody-mediated immunity in the female genital tract [9, 50]. Our team recently completed a Phase 1 clinical trial in women that tested the safety, pharmacokinetics, and ex vivo efficacy of a topically-applied vaginal film, MB66, containing IgG1 mAbs against HIV-1 and HSV-2 that had been produced in Nicotiana. Daily vaginal application of MB66 film for seven days did not cause notable adverse events, and the concentration of active mAbs present in vaginal secretions 24 h after film application was sufficient to prevent HIV-1 and HSV-2 infection ex vivo (concentration range: 36–700 μg/ml) [12]. The HCA experiments in the present study were conducted using antibody concentrations within the range of mAbs present in vaginal secretions 24 h post-film application. Taken together, the data on HCA specificity, efficacy and safety from the present study, combined with the results from the MB66 clinical trial indicate that HCA is a promising candidate for use as a topical vaginal contraceptive.

Due to its activity and safety profile, HCA could address current gaps in the contraception field. However, one of the limitations of antibody therapeutics is their high cost [54]. New production platforms such as Nicotiana, Trichoderma, and second generation Chinese hamster ovary (CHO) systems are projected to bring the cost of mAbs
down to approximately $10/gram, making it feasible to use mAbs for contraception and MPT applications [9]. More potent bispecific and multivalent monoclonal antibodies are also being engineered [55] and could further reduce cost as less product would be required for clinical efficacy. Next generation vaginal delivery methods such as long-acting intravaginal rings [56] could further reduce product cost, and increase efficacy and user acceptability. If these projected cost-savings can be achieved, HCA could be accessible to women worldwide [57–59]. There are other limitations of the current study that will need to be addressed in future research. Only a small number of sperm donors were used for this study (n = 10), and those men were primarily Caucasian. Although, HCA was effective in all of these donors, more research is required to determine whether there is increased variability in the effects of HCA on sperm agglutination among some groups of men, especially in those from different races. Another potential limitation of this research is that HCA could interfere with normal functions of CD52g, which are largely unknown. A report from Flori et al. [60] provided evidence that CD52g anchors sperm to semenogelin in the semen clot that forms minutes after intercourse; it is unknown whether HCA affects this process. A final limitation is that the study was conducted in vitro, and a clinical trial will be required to determine the in vivo contraceptive efficacy of HCA. Indeed, we are currently conducting an exploratory Phase I mechanism-of-action study of HCA.

HCA has the potential to be combined with other antibodies or small molecules, without altering its efficiency. A vaginal MPT product containing a combination of contraceptive and anti-microbial mAbs (e.g., HCA, VRC01, and HSV8) could provide a safe, accessible, and effective solution to address an urgent unmet global need [7, 61–63].

**Funding**

This research was supported by grants R01 HD095630 and P50 HD096957 from the National Institutes of Health.

**Data sharing statement**

Data supporting the findings of this study are available within the manuscript, and are also available from the authors upon reasonable request.

**Declaration of Competing Interest**

LZ and KJW own Mapp Biopharmaceutical Inc., a company interested in commercializing contraceptive antibodies. TRM, MB, and MP are employees of Mapp Biopharmaceutical Inc. The other authors (GBV, JCM, JAP, EM, JP, JD, EN, DJA) have no conflict of interest.

**Acknowledgments**

We thank Drs. Catherine Costello and Suryaram Gummuru for reading initial drafts of this manuscript and offering constructive feedback.

**Supplementary materials**

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ebiom.2021.103478.

**References**

[1] Anderson DJ. Population and the environment-time for another contraception revolution. N Eng J Med 2019;381(5):397–9.

[2] World Population Prospects 2019: Highlights [ST/ESA/SER.A/423]. United Nations 2019.

[3] Cheetoh JJ, McMahon SA, Greenspan JA, Mosha IH, Callaghan-Koru JA, Kilweso J, et al. Every method seems to have its problems—perspectives on side effects of hormonal contraceptives in Morogoro region, Tanzania. BMC Women's Health 2015;15(1):97.

[4] Roach REJ, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Comparative contraceptive effects of the natural menopause and medical menopause. Cochrane Database Syst Rev 2015(8):CD011054.

[5] Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiatry 2016;73(11):1154–62.

[6] Contraception Reproductive health CDC [internet]. 2018. Available from: https://www.cdc.gov/reproductivehealth/contraception/index.htm.

[7] Hynes JS, Sales JM, Seth LJ, Haddad LB. Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United States. Contraception 2017;97:277–84.

[8] Minus AM, Browne EN, Boeri M, Agot K, Stratton A, Ahmed K, et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defy Syndr 2019;94:401–4.

[9] Anderson DJ, Politch JA, Zettlin I, Hiatt A, Kadasia K, Mayer KH, et al. Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. AIDS 2017;31(1):1105–17.

[10] vxx. Antibody therapeutics approved or in regulatory review in the EU or US. The Antibody Society; 2021.

[11] Haynes BF, Burton DR, Mascola JR. Multiple roles for HIV broadly neutralizing antibodies. Sci Transl Med 2019;11(516):eaaz2680.

[12] Politch JA, Cu-Uvin S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, et al. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention device (MB66): a phase I randomized trial. PLoS Med 2021;18(2):e1005495.

[13] Barbonetti A, Castellini C, D’Andrea S, Minaldi E, Totaro M, Francavilla S, et al. Relationship between natural and intrauterine insemination-assisted live births and the degree of sperm autoimmunisation. Hum Reprod 2020;35(6):1288–95.

[14] Bohring C, Krause W. Immune infertility: towards a better understanding of sperm (auto-)immunity. The value of proteomic analysis. Hum Reprod 2003;18(5):915–24.

[15] Price RJ, Boettcher B. The presence of complement in human cervical mucus and its possible relevance to infertility in women with complement-dependent sperm-immobilizing antibodies. Fertil Steril 1979;32(1):61–6.

[16] Tsuji Y, Clausen H, Nudelman E, Kaizu T, Hakomori S, Isojima S. Human sperm carbohydrate antigens defined by an antisperm human monoclonal antibody derived from an infertile woman bearing antisperm antibodies in her serum. J Exp Med 1988;168(1):343–56.

[17] Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, et al. CD52 antigen expressed by malignant plasma cells can be targeted by alentuzumab in vivo in NOD/SCID mice. Exp Hematol 2006;34(6):721–7.

[18] Isojima S, Kameda K, Tsuji Y, Shigeta M, Ikeda Y, Koyama K. Establishment and characterization of a human hybridoma secreting monoclonal antibody with high titers of sperm immobilizing and agglutinating activities against human seminal plasma. J Reprod Immunol 1987;10(1):57–78.

[19] Komori S, Yamasaki N, Shigeta M, Isojima S, Watanabe T. Production of heavy chain-class switch variants of human monoclonal antibody by recombinant DNA technology. Clin Exp Immunol 1988;71(3):508–16.

[20] Klimyk V, Pogue G, Herz S, Butler J, Haydon H. Production of recombinant antigens and antibodies in nicotiana benthamiana using ‘magnification’ technology: GMP-compliant facilities for small- and large-scale manufacturing. Curr Top Microbiol Immunol 2014;375:127–54.

[21] Strasser R, Stadtmann J, Schahi M, Stiegl M, Quendler H, Mach L, et al. Generation of glyco-engineered nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure: YfT and FucT down-regulation in N. benthamiana. Plant Biotechnol 2008;6:394–402.

[22] Zettlin L, Bohorov O, Bohorov N, Hiatt A, Kim DH, Phany MH, et al. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. Mabs 2013;5(2):263–9.

[23] xxx. WHO laboratory manual for the examination and processing of human semen. Geneva: World Health Organization; 2010.

[24] Sobrero AJ. Sperm migration in the human female: further clinical observations. J. Sex Res. 1967;3(4):319–22.

[25] Fordoe Settlage DS, Motoshiba M, Tredway DR. Sperm transport from the external cervical Os to the fallopian tubes in women: a time and quantitation study. Microbiol Immunol 2014;375:127–54.

[26] Strasser R, Stadtmann J, Schahi M, Stiegl M, Quendler H, Mach L, et al. Generation of glyco-engineered nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure: YfT and FucT down-regulation in N. benthamiana. Plant Biotechnol 2008;6:394–402.

[27] Zeilin L, Bohorov O, Bohorov N, Hiatt A, Kim DH, Phany MH, et al. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. Mabs 2013;5(2):263–9.
vesicle-specific peptides: a novel probe/marker system for semen identification. Biol Reprod 1986;35(3):773–84.

[31] Norton EJ, Diekman AB, Westbrook VA, Mullins DW, Klitz KL, Gilmer LL, et al. A male genital tract-specific carbohydrate epitope on human CD52: Implications for immunocontraception. Tissue Antigens 2002;60(3):354–64.

[32] Diekman AB, Norton EJ, Westbrook VA, Klitz KL, Naaby-Hansen S, Herr JC. Anti-sperm antibodies from infertile patients and their cognate sperm antigens: a review. identity between SAGA-1, the H6-3C4 antigen, and CD52. Am J Reprod Immunol 2008;43(3):134–43.

[33] EuroMABNet. Production of large quantities of monoclonal antibodies protocol. 2021.

[34] Fichorova RN, Rheinwald JG, Anderson DJ. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 1997;57(4):847–55.

[35] Ayehunie S, Cannon C, Lamore S, Kubilus J, Anderson DJ, Pudney J, et al. Organocult of cervicovaginal fluid is altered during bacterial vaginosis. J Low Genit Tract Dis 2015;19(2):106 (2, Part A).

[36] Hellema HW, Risman P. The micro-sperm immobilization test: the use of only motile spermatozoa and studies of complement. Clin Exp Immunol 1978;31(1):1–11.

[37] Itojima S, Koyama K. Techniques for sperm immobilization test. Arch Androl 1989;23(3):185–99.

[38] Zyl JA, Menkveld R, Potze TJ, Retief AE, Nierkerk WA. Oligozoospermia: a seven-year survey of the incidence, chromosomal aberrations, treatment and pregnancy rate. Int J Fertil 1975;20(3):129–32.

[39] Zyl JAV, Menkveld R. Oligozoospermia: recent prognosis and the outcome of 73 pregnancies in oligozoospermic couples. Andrologia 2006;38(3):87–91.

[40] Long JE, Lee MS, Blithe DL. Update on novel hormonal and nonhormonal male contraceptive development. J Clin Endocrinol Metab 2021;106(6):e2381–e92.

[41] Fox CA, Meldrum SJ, Watson BW. Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil 1973;33(1):69–75.

[42] O’Hallon DE, Moench TR, Cone KA. Vaginal pH and microbial lactic acid when lactobacilli dominate the microbiota. PLOS ONE 2013;8(11):e80074.

[43] Aldunate M, Srinovinski D, Hearps AC, Latham CF, Rasmund PA, Guayyan R, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol 2015;6:164.

[44] Shaw JT, Smith CR, Diamantis EP. Proteomic analysis of human cervico-vaginal fluid. J Proteom Res 2007;6(7):2859–65.

[45] Ferrera CST, da Silva MG, de Pontes LG, Dos Santos LD, Marconi C. Protein content of cervico-vaginal fluid is altered during bacterial vaginosis. J Low Genit Tract Dis 2018;22(2):147–51.

[46] Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007;13(7):491–501.

[47] Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 2012;188(5):2445–54.

[48] Kremer J, Jager S. The significance of antisperm antibodies for sperm-cervical mucus interaction. Hum Reprod 1992;7(6):781–4.

[49] Berard AR, Perner M, Mutch S, Zueid CF, McQueen P, Burgener AD. Understanding mucosal and microbial functionality of the female reproductive tract by meta-proteomics: implications for HIV transmission. Am J Reprod Immunol 2018;80(2):e12977.

[50] Hickey DK, Patel MV, Faby IV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011;88(2):185–94.

[51] Kutteh WH, Mestecy J. Secretory immunity in the female reproductive tract. Am J Reprod Immunol 1994;31(1):40–6.

[52] Lee SK, Kim CJ, Kim D-J, Kang J-H. Immune cells in the female reproductive tract. Immune Netw 2015;15(1):16–26.

[53] Singh SK. Diagnostics to pathogenomics of sexually transmitted infections. Hoboken, NJ: John Wiley & Sons; 2018.

[54] Sonfeld A, Hasstedt K, Gold RB. Moving forward: family planning in the era of health reform. New York: Guttmacher Institute; 2014.

[55] Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for biocidal antibodies. Mol Immunol 2015;67:95–106 (2, Part A).

[56] Zhao C, Gunawardana M, Villingler F, Baum MM, Remedios-Chan M, Moench TR, et al. Pharmakokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother 2017;61(7):e02615-16.

[57] Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception 2007;75(6):527–7 Supplement.

[58] The ESIRRE capri workshop group: intrauterine devices and intrauterine systems. Hum Reprod Update 2008;14(3):197–208.

[59] Ruhling KJ, Zite NB, Lotke P, Black K. Worldwide use of intrauterine contraception: a review. Contraception 2014;89(3):162–73.

[60] Fiori F, Ermini L, La Sala GB, Nicolì A, Capone A, Focarelli R, et al. The GPI-anchored CD52 antigen of the sperm surface interacts with semenogelin and participates in sperm-cervical antibodies. Mol Immunol 2015;67:95–106 (2, Part A).

[61] Chang C, Gunawardana M, Villingler F, Baum MM, Remedios-Chan M, Moench TR, et al. Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother 2017;61(7):e02615-16.

[62] McConville C, Major I, Devlin B, Brimer A. Development of a multi-layered vaginal microsperm immobilization test: the use of only motile spermatozoa and studies of complement. Clin Exp Immunol 1978;31(1):1–11.

[63] Itojima S, Koyama K. Techniques for sperm immobilization test. Arch Androl 1989;23(3):185–99.

[64] Zyl JA, Menkveld R, Potze TJ, Retief AE, Nierkerk WA. Oligozoospermia: a seven-year survey of the incidence, chromosomal aberrations, treatment and pregnancy rate. Int J Fertil 1975;20(3):129–32.

[65] Zyl JAV, Menkveld R. Oligozoospermia: recent prognosis and the outcome of 73 pregnancies in oligozoospermic couples. Andrologia 2006;38(3):87–91.

[66] Long JE, Lee MS, Blithe DL. Update on novel hormonal and nonhormonal male contraceptive development. J Clin Endocrinol Metab 2021;106(6):e2381–e92.

[67] Fox CA, Meldrum SJ, Watson BW. Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil 1973;33(1):69–75.

[68] O’Hallon DE, Moench TR, Cone KA. Vaginal pH and microbial lactic acid when lactobacilli dominate the microbiota. PLOS ONE 2013;8(11):e80074.

[69] Aldunate M, Srinovinski D, Hearps AC, Latham CF, Rasmund PA, Guayyan R, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol 2015;6:164.

[70] Shaw JT, Smith CR, Diamantis EP. Proteomic analysis of human cervico-vaginal fluid. J Proteom Res 2007;6(7):2859–65.

[71] Ferrera CST, da Silva MG, de Pontes LG, Dos Santos LD, Marconi C. Protein content of cervico-vaginal fluid is altered during bacterial vaginosis. J Low Genit Tract Dis 2018;22(2):147–51.

[72] Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007;13(7):491–501.